Abstract
Problem statement: The literature is reviewed and supports a strong anecdotal relationship between bromocriptine use and psychosis. It is well known that any interference with brain amino acid levels is likely to lead to disorder. Our previous research has shown that bromocriptine produced significant changes in the heart and kidneys amino acid contents. It has been confirmed that the brain amino acids concentrations are influenced by plasma amino acid levels. Therefore, it is the thought of interest to investigate the effect of bromocriptine, sulpiride or their combination on the brain and plasma amino acid concentrations of rat. Approach: The influence of chronic treatment with bromocriptine 20 mg kg day-1 i.p, sulpiride 20 mg kg day-1 i.p. or their combination bromocriptine 20 mg kg day-1 i.p + sulpiride 20 mg kg day-1 i.p. for 6 weeks on free amino acids in the brain and the plasma of rats were carried out. The amino acids were quantified using the LKB 4400 Amino Acid Analyzer and the Hami1ton’s amino acid calibration standards. Results: Bromocriptine significantly decreased the plasma content of glutamic acid, glycine and alanine. (p<0.05, n = 7). Sulpiride did not affect basal or bromocriptine-induced changes in the plasma amino acid concentrations. Also, results indicate that bromocriptine decreased the brain content of taurine, glycine and aspartic acid. The mean % decreases were 40±3, 55±6 and 30±4 respectively (p<0.01, n = 7). Sulpiride prevented the decreases in glycine and aspartic acid only. Conclusion: This study provided evidence for the possible involvement of some amino acids in mediating some actions of bromocriptine. Our previous results presented evidence for the antagonistic effect of taurine on some bromocriptine-induced actions that probably involve activation of 5-HT receptors. As a result, bromocriptine-induced depletion of brain taurine, which involved activation seretonergic receptors, may underlie the appearance of some side effects of bromocriptine such as hallucinations in Parkinson’s patients. Thus, bromocriptine induced hallucination is related to non dopaminergic action. Further, the results direct the attention to the possible involvement of glycine, aspartic and glutamic in bromocriptine induced schizophrenia. This study indicates that different mechanisms of the etiology of schizophrenia which are not possible based upon dopaminergic mechanism alone.
Highlights
Bromocriptine (2-bromo-a-ergocriptine) is an ergot polypeptide derivative that combines with dopamine receptors in various tissues (Johnson et al, 1976)
Percentage recovery of the free amino acids: Analysis of known concentrations of standard Amino acids exposed to the same extraction procedure as the tissues showed that the percentage recovery for the various amino acids a ranged from 97.5±1.0 for glycine to 99±1 taurinc, other amino acids were within this range
It seems likely that bromocriptine induced hallucination is related to non dopaminergic action
Summary
Bromocriptine (2-bromo-a-ergocriptine) is an ergot polypeptide derivative that combines with dopamine receptors in various tissues (Johnson et al, 1976). Sulpiride is an antipsychotic drug that acts as a selective blocking agent of pre-and post dopamine receptors (Alander et al, 1980). Bromocriptine is be1ieved to decrease plasma prolactin levels by activating central dopaminergic receptors in various mammals (Brooks and Welsch, 1974). A single injection of the compound into rats induced a decrease in plasma prolactin levels that lasted several days, albeit it’s short half-life in the plasma (Brooks and Welsch, 1974).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
